✦ LIBER ✦

A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy

✍ Scribed by Lang, Joshua M.; Wallace, Marianne; Becker, Jordan T.; Eickhoff, Jens C.; Buehring, Bjoern; Binkley, Neil; Staab, Mary Jane; Wilding, George; Liu, Glenn; Malkovsky, Miroslav; McNeel, Douglas G.

Book ID: 122380777
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 812 KB
Volume: 11
Category: Article
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2013.04.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Zoledronic Acid Initiated During the

Re: Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer

✍ Gilbert, Scott M.; Dunn, Rodney L.; Wei, John T. 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 50 KB

MP-08.12: One single dose of zoledronic

MP-08.12: One single dose of zoledronic acid (Zometa) annually can prevent bone mineral density (BMD) in patients with prostate cancer treated with LHRH: early results of a randomized trial

✍ A. Lekas; M. Chrisofos; I. Fokitis; A. Balangas; A. Kollias; C. Deliveliotis 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 87 KB

8544 A prospective, open-label, randomiz

8544 A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM)

✍ Zhao, Y.; Liao, H.; Hou, X.; Sun, J.; Guo, Y.; Li, S.; Zhang, L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Phase II Trial Evaluating the Palliative

Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy

✍ Brufsky, A.M. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A phase II trial evaluating the palliati

A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases despite standard bisphosphonate (BP) therapy

✍ M. Clemons; G. Dranitsaris; W.S. Ooi; D.E.C. Cole 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 51 KB